ArticleOncoimmunology2023

Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.

Alisa Lepper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.